Ashley Chan

WT-7 demonstrated a 91% overall response rate and 73% composite complete response rate in relapsed/refractory T-ALL/LBL patients.

Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

Duvelisib plus venetoclax is effective in relapsed/refractory CLL and RS, especially in high-risk TP53-aberrant patients and those post-BTK inhibitor treatment.

Abenacianine (VGT-309) received FDA fast track designation to improve intraoperative visualization of lung cancer and related lesions.

An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

Martin Dreyling, MD, PhD, discusses the role of ASCT with or without an ibrutinib-based regimen in younger patients with mantle cell lymphoma.

Ira Zackon, MD, discusses real-world observational data on bispecific antibody use in community oncology in patients with relapsed/refractory multiple myeloma.

ELC-100, an oncolytic virus, targets pancreatic neuroendocrine tumors and has received FDA orphan drug designation.

AVA6000 showed clinically meaningful tumor shrinkage in FAP-positive salivary gland cancer, with a 90% disease control rate in the trial cohort.

Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.